title: Neuroimaging in Huntington's disease.
abstract: Huntington's disease (HD) is a progressive and fatal neurodegenerative disorder caused by an expanded trinucleotide CAG sequence in huntingtin gene (HTT) on chromosome 4. HD manifests with chorea, cognitive and psychiatric symptoms. Although advances in genetics allow identification of individuals carrying the HD gene, much is still unknown about the mechanisms underlying the development of overt clinical symptoms and the transitional period between premanifestation and manifestation of the disease. HD has no cure and patients rely only in symptomatic treatment. There is an urgent need to identify biomarkers that are able to monitor disease progression and assess the development and efficacy of novel disease modifying drugs. Over the past years, neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have provided important advances in our understanding of HD. MRI provides information about structural and functional organization of the brain, while PET can detect molecular changes in the brain. MRI and PET are able to detect changes in the brains of HD gene carriers years ahead of the manifestation of the disease and have also proved to be powerful in assessing disease progression. However, no single technique has been validated as an optimal biomarker. An integrative multimodal imaging approach, which combines different MRI and PET techniques, could be recommended for monitoring potential neuroprotective and preventive therapies in HD. In this article we review the current neuroimaging literature in HD.
authors: Flavia Niccolini, Marios Politis, Neurodegeneration Imaging Group, Department of Clinical Neuroscience, King's College London, London SE5 8AF, United Kingdom.
authors: Flavia
authors: F
authors: Niccolini
authors: Flavia Niccolini, Marios Politis, Neurodegeneration Imaging Group, Department of Clinical Neuroscience, King's College London, London SE5 8AF, United Kingdom.
authors: Marios
authors: M
authors: Politis
keywords: Functional magnetic resonance imaging; Huntington’s disease; Magnetic resonance imaging; Positron emission tomography; Premanifest Huntington’s disease gene carriers